Stress-Selected Enduring Cells — a refined evolution of MUSE-cell methodology, engineered for the resilience, purity, and clinical consistency that modern regenerative medicine demands.
Within every mesenchymal stem cell population lives a small, exceptional subset of cells — biologically more resilient, more potent, and more pluripotent-like than the rest. ATOM SSEC™ exists to isolate that subset with the consistency a clinical-grade product requires.
The science we build on isn't ours. The production process is.
In 2010, researchers led by Dr. Mari Dezawa at Tohoku University identified a rare subpopulation of cells living quietly inside ordinary mesenchymal stem cell cultures. These cells — multilineage-differentiating, stress-enduring — became known as MUSE cells.
What made them remarkable: they survived stress conditions that killed every cell around them. They expressed SSEA-3, a pluripotency marker normally seen on embryonic stem cells. And they could differentiate into cells from all three germ layers — a property previously thought to require embryonic origin.
MUSE cells exist in nature. The challenge was never proving they existed. The challenge was producing them with the consistency a clinical-grade product requires.
Cells that survive what should kill them aren't surviving by luck — they're surviving because of fundamental biological differences that translate directly to clinical performance.
SSEC™ cells survive conditions — long-term trypsin exposure, serum starvation, hypoxia — that eliminate ordinary MSCs within hours. The cells that endure are the ones with intact stress-response machinery, robust mitochondria, and superior metabolic flexibility.
SSEC™ cells express SSEA-3 — a marker normally restricted to embryonic stem cells — and demonstrate multilineage differentiation capacity. They are not embryonic, but they retain a developmental flexibility that ordinary MSCs have already lost.
Resilient cells communicate more effectively. SSEC™ cells produce a richer exosome profile and a stronger anti-inflammatory secretome, translating into the kind of regenerative signaling that drives clinical outcomes in modern regenerative medicine.
Six stages, each one engineered for what we couldn't get from off-the-shelf MUSE methodology: clinical-grade consistency, batch-to-batch reproducibility, and integration with modern 3D bioreactor systems.
The process begins with high-viability mesenchymal stem cells isolated from Wharton's Jelly — the gelatinous tissue inside the umbilical cord. These cells are biologically young, immunologically privileged, and inherently rich in the rare subpopulation we're targeting.
Source qualification: Every donor undergoes full screening per FDA HCT/P guidelines. Each lot is traceable back to the source.
The MSC population is subjected to a precisely calibrated stress protocol — extended enzymatic exposure under serum-restricted conditions. Ordinary MSCs cannot survive these conditions. The rare resilient subset can.
This is the heart of the process. The stress isn't damaging the surviving cells — it's revealing the ones that were already different.
The cells that endure the stress phase are isolated, washed, and transferred into recovery media. At this stage we have a highly enriched population of stress-selected cells — the foundation for SSEC™.
Cell viability is confirmed before any cells advance to the next stage.
The enriched population is characterized to confirm pluripotent-like identity. SSEA-3 expression is verified alongside standard MSC surface markers and viability indicators.
This is the gate that no other commercial source consistently meets. Most "MUSE-equivalent" products don't run this verification on every lot. We do.
Verified SSEC™ cells move into 3D microcarrier-based suspension culture — the same physiologically relevant environment we use across our MSC products. This preserves the cells' pluripotent-like markers, supports robust paracrine output, and produces the lot volumes clinical applications require.
This is one of the biggest departures from legacy MUSE-cell production, which typically relied on 2D flask culture and suffered the consistency problems that come with it.
Every SSEC™ lot is released only after independent third-party laboratory testing. Identity, viability, sterility, and purity are confirmed before any vial leaves the facility.
Lot certificates of analysis are made available to every clinical partner. Traceability is not a marketing claim — it's a documented requirement of the release process.
The science is the same. The production process — and what that production process is capable of delivering — is where the products separate.
These are the markers that distinguish SSEC™ from ordinary MSCs — and the ones we test for on every lot, with results that travel with every vial.
The defining surface marker of stress-selected pluripotent-like cells. SSEA-3 is normally restricted to embryonic stem cells — its presence on SSEC™ is what places these cells in the pluripotent-like category. Verified on every lot.
Standard mesenchymal stem cell identity markers — including CD73, CD90, and CD105 expression alongside the absence of hematopoietic markers — confirm the cells retain their MSC identity even after stress selection. Tested per ISCT criteria.
Live-cell viability, sterility testing, and endotoxin levels are confirmed by independent third-party laboratories before lot release. No lot is released without a clean certificate of analysis.
SSEC™ cells are expanded in the same 3D microcarrier bioreactor environment we use across our MSC product line. Read Volume II to understand why three-dimensional culture is fundamental to the consistency and potency of every SSEC™ lot.
ATOM SSEC™ — the refined evolution of MUSE-cell science, produced for the consistency and scalability clinical regenerative medicine has always needed.
View Products